Table 2.

Discordant cases (≥2 of the 3 breast cancer experts)

Case	WfO	Experts	Key characteristics
1	CMF	ACT, ACT, TC	66 y, stage IA, pT1cN0, ductal, high grade, ER/PR+, her2−, oncotype high
2	Hormonal	CMF, CMF, CMF	85 y, stage IIIA, pT2N2a, 5 + LN, ductal, high grade, ER/PR+, her2−, lym‐vasc inv+
3	CMF	Hormonal, hormonal	77 y, stage IA, pT1bN0, mix histology, inter grade, ER+, PR−, her2−, oncotype intermed
4	CMF, ACT	Hormonal, TC	57 y, stage IIA, T2N0, ductal, interm grade, ER/PR+, her2−, oncotype inter, lym‐vasc+
5	ACT	Hormonal, CMF	73 y, stage IIA, pT1mi, 1 LN (2 mm), ductal, interm grade, ER/PR−, her2−, lym‐vasc−
6	ACT	Hormonal, CMF	75 y, stage IA, pT1cN0, ductal, high grade, ER/PR/her2−, lym‐vasc−
7	Hormonal	ACTH, TH	64 y, recurrent chest wall with movable LN, prior AC 36 mo, ER/PR/her2+

Abbreviation: ACT: doxorubicin, cyclophosphamide, docetaxel; ACTH: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab; CMF: cyclophosphamide, methotrexate, 5‐fluorouracil; TC: docetaxel, cyclophosphamide; TH: paclitaxel, trastuzumab; WfO, Watson for Oncology.